Puff Daddy ** OT ** ATVH, I couldn't resist. Take a "puff" on this one. Just announced earnings, $850K on 904K sales !!!!!!
"just one word here,..."plastics" Plastic cigarettes, to help quit smoking (no joke) guaranteed 15% in dividends !!!!!
ATP Announces Profits
PR Newswire - May 05, 1999 12:56
SAN ANTONIO, May 5 /PRNewswire/ -- Advanced Therapeutic Products, Inc. (OTC Bulletin Board: AVTH) (ATP) today reported after tax earnings of $853,592 (10.5 cents per share) on revenues of $904,230 for the nine month period ending March 31, 1999, as compared to $238,196 (3.0 cents per share) on revenues of $285,541 for the nine month period ending March 31, 1998. ATP's after tax earnings for the fiscal year ending June 30, 1998, was 6.0 cents per share.
For the three month period ending March 31, 1999, after tax earnings were $222,756 (2.8 cents per share) on revenues of $234,330 as compared to earnings of $148,544 (1.8 cents per share) on revenues of $162,385 for the three month period ending March 31, 1998.
ATP paid an annual dividend of 7.0 cents per share in January, 1999, for its fiscal year ending June 30, 1998. ATP expects to pay an annual dividend of 10.0 to 15.0 cents per share in January, 2000, for its fiscal year ending September 30, 1999.
In 1987, ATP sold patented nicotine technology, which forms the basis of the Nicorette(R)/Nicotrol(R) Inhaler, to what is now Pharmacia & Upjohn, in exchange for product payments. Product payments from the sales of the Nicorette(R) Inhaler in Europe are 3% of Pharmacia & Upjohn's net sales to pharmacy distributors. Product payments from the sales of the Nicotrol(R) Inhaler in the U.S. are 9.9% of Pharmacia & Upjohn's net sales to McNeil Consumer Products, a Johnson & Johnson Company, which markets the Inhaler to pharmacies as a prescription product.
In early September 1998, McNeil launched the Nicotrol(R) Inhaler nationwide in the U.S. as a prescription product (the U.S. is approximately 50% of the worldwide nicotine replacement therapy ("NRT") market). Pharmacia & Upjohn has also introduced the Nicorette(R) Inhaler, primarily as an over- the-counter product, in the United Kingdom, New Zealand, Ireland, Norway, Sweden, Denmark, Italy, Austria, The Netherlands, Belgium, Finland, Iceland, Gibraltar and Hong Kong. ATP understands that additional country launches are planned by Pharmacia & Upjohn to occur as regulatory approvals are granted.
The Nicorette(R)/Nicotrol(R) Inhaler is the first and only form of NRT designed to help control a smoker's cravings for cigarettes while providing a key behavioral component of smoking--the hand-to-mouth ritual. The Inhaler consists of a mouthpiece and a cartridge containing nicotine. The user puffs on the mouthpiece to inhale the nicotine which is then absorbed through the lining of the mouth. The Inhaler provides about 30% of the nicotine a smoker gets from cigarettes. It does not contain any of the harmful substances like tar and carbon monoxide found in tobacco smoke which cause smoking related diseases like lung cancer.
ATP ("Advanced Tobacco Products, Inc.," d/b/a Advanced Therapeutic Products, Inc.) is quoted on the OTC Bulletin Board under the symbol AVTH.
Contact: Jim Linehan, President of Advanced Therapeutic Products, Inc., 210-408-7077, or Fax, 210-408-7077. For other company news go to prnewswire.com.
SOURCE Advanced Therapeutic Products, Inc. |
